| [1] | HUANG H F, CHOPRA R, VERDINE G L, et al. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: Implications for drug resistance[J]. Science, 1998, 282: 1669-1675.
|
| [2] | JOSEPH J E, CHRISTINE M H. Entry and fusion inhibitors: An update[J]. The PRN Notebook, 2002, 7(1):
|
| [3] | 16-22.
|
| [4] | SATTENTAU Q J, MOORE J P. Conformational changes induced in the human immunodeficiency virus
|
| [5] | venelope glycoprotein by soluble CD4 binding[J]. J Exp Med, 1991, 174: 407-415.
|
| [6] | ECKERT D M, MALASHKEVICH V N, HONG L H, et al. Inhibiting HTV-1 entry: Discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket[J]. Cell, 1999, 99: 103-115.
|
| [7] | DAVID C C, PETER S K. HIV entry and its inhibition[J]. Cell, 1998, 93: 681-684.
|
| [8] | SCHACKER T, COLLIER A C, COOMBS R, et al. Phase I study of high-dose, intravenous rsCD4 in
|
| [9] | subjects with advanced HTV-1 infection[J]. J Acquir Immune Defic Syndr Hum Retrovirol, 1995, 9: 145-152.
|
| [10] | ASHKENAZI A, SMITH D H, MARSTERS S A, et al. Resistance of primary isolates of human
|
| [11] | immunodeficiency virus 1 to soluble CD4 is independent of CD4-rgp120 binding affinity[J]. Proc Natl Acad Sci
|
| [12] | USA, 1991, 88: 7056-7060.
|
| [13] | JACOBSON J M, LOWY I, FLETCHER C V, et al. Single-dose safety, pharmacology, and antiviral activity
|
| [14] | of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults[J]. J Infect
|
| [15] | Dis, 2000, 182(1): 326-329.
|
| [16] | 谭建军，张晓轶，马小慧，等．HIV—1辅助受体的研究进展[J]．北京工业大学学报，2003，29(1)：59-63． TAN Jian-jun, ZHANG Xiao-yi, MA Xiao-hui, et al. Research progress of HTV-1 coreceptor-chemokine receptor[J]. Journal of Beijing University of Technology, 2003, 29(1): 59-63. (in Chinese)
|
| [17] | DEAN M, CARRINGTON M, WINKLER C, et al. Genetic restriction of HTV-1 infection and progression to
|
| [18] | AIDS by a deletion allele of the CCR5 structural gene[J]. Science, 1996, 273: 1856-1862.
|
| [19] | ZHOU N, LUO Z, LUO J, et al. A novel peptide antagonist of CXCR4 derived from the N-terminus of viral chemokine vMTP-II[J]. Biochemistry, 2000, 39(13): 3782-3787.
|
| [20] | TRKOLA A, KETAS T J, NAGASHIMA K A, et al. Potent, broad-spectrum inhibition of human
|
| [21] | immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140[J]. J Virol, 2001, 75: 579-588.
|
| [22] | STRIZKI J M, XU S, WAGNER N E, et al. SCH-C (SCH 351125), an orally bioavailable, small molecule
|
| [23] | antagonist of the chemokine receptor CCR5, is a potent inhibitor of HTV-1 infection in vitro and in vivo[J].
|
| [24] | Proc Natl Acad Sci USA, 2001, 98(22): 12718-12723.
|
| [25] | FARZAN M, VASILIEVA N, CHRISTINE E, et al. A tyrosine-sulfated peptide based on the N terminus of
|
| [26] | CCR5 interacts with a CD4-enhanced epitope of the HTV-1 gp120 envelope glycoprotein and inhibits HTV-1
|
| [27] | entry[J]. J Biol Chem, 2000, 275(43): 33516-33521.
|
| [28] | CORMIER E G, TRAN D N H, YUKHAYEVA L, et al. Mapping the determinants of the CCR5 amino-t
|
| [29] | erminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes[J]. J
|
| [30] | Virol, 2001, 75: 5541-5549.
|
| [31] | CORMIER E G, PERSUH M, THOMPSON AD, et al. Specific interaction of CCR5 amino- terminal domain
|
| [32] | peptide s containing sulfo-tyrosmes with HTV-1 envelope glycoprotem gp120[J]. Proc Natl Acad Sci USA, 2000,
|
| [33] | 97: 5762-5767.
|
| [34] | UEKI M, WATANABE S, SAITOH T, et al. Synthesis and chain length-antiHIV-activity relationship of fully
|
| [35] | N- and O-sulfated homooligomers of tyrosine[J]. Bioorg Med Chem, 2001, 9(2): 487-492.
|
| [36] | CLERCQ E D. Novel compounds in preclinical/early clinical development for the treatment of HIV infections[J].
|
| [37] | Rev Med Virol, 2000, 10: 255-277.
|
| [38] | RUSCONI S, CATAMANCIO LA SETA S, CITTERIO P, et al. Combination of CCR5 and CXCR4 inhibitors
|
| [39] | in therapy of human immunodeficiency virus type 1 infection: In vitro studies of mixed virus infections[J]. J
|
| [40] | Virol, 2000, 74: 9328-9332.
|
| [41] | SU S B, GONG W H, GAO J L, et al. T20/DP178, an ectodomain peptide of human immunodeficiency virus
|
| [42] | type 1 gp41, is an activator of human phagocyte N-formyl peptide receptor[J]. Blood, 1999, 93(11):
|
| [43] | 3885-3892.
|
| [44] | LIN P F, SAMANTA H, BECHTOLD C M. Characterization of siamycin I, a human immunodefciency virus
|
| [45] | fusion inhibitor[j]. Antimicrob Agents Chemother, 1996, 40: 133-138.
|
| [46] | CHAN D C, CHUTKOWSKI C T, KIM P S. Evidence that a prominent cavity in the coiled coil of HIV type
|
| [47] | 1 gp41 is an attractive drug target[J]. Proc Natl Acad Sci USA, 1998, 95: 15613-15617.
|
| [48] | SIA S K, CARR P A, COCHRAN A G, et al. Short constrained peptides that inhibit HIV-1 entry[J]. Proc
|
| [49] | Natl Acad Sci USA, 2002, 99(23): 14664-14669.
|
| [50] | MAYAUX J-F, BOUSSEAU A, PAUWELS R, et al. Triterpene derivatives that block entry of human
|
| [51] | immunodeficiency virus type 1 into cells[J]. Proc Natl Acad Sci USA, 1994, 91: 3564-3568.
|
